Based on the key indicators related to DBV Technologies' liquidity, profitability, solvency, and operating efficiency, DBV Technologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, DBV Technologies' Non Current Liabilities Total is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 344.6 M in 2025, whereas Current Deferred Revenue is likely to drop slightly above 243.6 K in 2025. Key indicators impacting DBV Technologies' financial strength include:
Investors should never underestimate DBV Technologies' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor DBV Technologies' cash flow, debt, and profitability to make informed and accurate decisions about investing in DBV Technologies.
Understanding current and past DBV Technologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DBV Technologies' financial statements are interrelated, with each one affecting the others. For example, an increase in DBV Technologies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in DBV Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DBV Technologies. Check DBV Technologies' Beneish M Score to see the likelihood of DBV Technologies' management manipulating its earnings.
DBV Technologies Stock Summary
DBV Technologies competes with GH Research, Inventiva, Genfit SA, CytomX Therapeutics, and Aclaris Therapeutics. DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what DBV Technologies' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining DBV Technologies's current stock value. Our valuation model uses many indicators to compare DBV Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DBV Technologies competition to find correlations between indicators driving DBV Technologies's intrinsic value. More Info.
DBV Technologies is rated # 5 in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, DBV Technologies' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value DBV Technologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
DBV Technologies Systematic Risk
DBV Technologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DBV Technologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on DBV Technologies correlated with the market. If Beta is less than 0 DBV Technologies generally moves in the opposite direction as compared to the market. If DBV Technologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DBV Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DBV Technologies is generally in the same direction as the market. If Beta > 1 DBV Technologies moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in DBV Technologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DBV Technologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of DBV Technologies growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of DBV Technologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DBV Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of DBV Technologies based on widely used predictive technical indicators. In general, we focus on analyzing DBV Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DBV Technologies's daily price indicators and compare them against related drivers.
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.